Evaluating outcomes of robotic surgery for bladder cancer
Official title: Impact of Robotic Surgery on Post-operative Outcomes of Patients Who Underwent Radical Cystectomy
Run by University of Florence · NCT04900558 · Data updated 2026-11-12
This study is testing how well robotic surgery for bladder cancer works compared to traditional surgery by looking at patients' recovery and outcomes over time.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | University of Florence Academic / other |
| Locations | 1 site (Florence, Tuscany) |
| Status | Recruiting |
| Started | April 29, 2021 |
| Main results expected | February 1, 2031 |
| Study ends | February 1, 2038 |
| Registry record updated | May 25, 2021 |
| Trial ID | NCT04900558 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older who are scheduled to undergo radical cystectomy for bladder cancer.
✕Probably not a fit
Patients who are unwilling to participate or refuse consent will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the long-term outcomes of patients undergoing radical cystectomy for bladder cancer, comparing results between robotic and open surgical approaches. It involves collecting data on perioperative, oncological, and functional results to understand the impact of robotic surgery in this context. Patients who are eligible and consent to participate will be monitored throughout their treatment process to gather comprehensive data on their recovery and outcomes.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effectiveness and advantages of robotic surgery for bladder cancer patients.
How similar studies have gone: Other studies have shown promising results with robotic surgical approaches in various oncological settings, suggesting potential for success in this study as well.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age major or equal 18 years * Patients who will undergo radical cystectomy * Consent to participate Exclusion Criteria: * Absence of willingness to participate * Further refusal to participate to the study
Where it's running
-
Careggi University Hospital
Florence, Tuscany, Italy Recruiting
Study contacts
- Principal investigator: Arcangelo Sebastianelli, MD — Careggi Hospital, University of Florence
- Study coordinator: Simone Morselli, MD
- Email: simone.morselli.89@gmail.com
- Phone: 3473050852
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy
This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.
-
Sexual health support after bladder cancer treatment
This project will try sexological support to help adults about 12 months after bladder cancer treatment improve sexual function and intimacy.
-
Ureteral stent versus no stent for adults having radical cystectomy with an ileal conduit
This trial tests whether placing temporary ureteral stents at the time of radical cystectomy with ileal conduit reduces post-operative complications compared with not placing stents in adults having cystectomy for bladder or other pelvic cancers.
-
Assessing late images in PET-CT for bladder cancer staging
This study is testing if taking later images during a PET-CT scan can help better identify lymph node involvement in patients with muscle-invasive bladder cancer.
-
Combining enfortumab vedotin and pembrolizumab with radiation for muscle invasive bladder cancer
This study is testing a new combination of a drug and radiation therapy to see if it helps people with muscle invasive bladder cancer who want to avoid surgery.
-
Neoadjuvant therapy for bladder cancer patients who can't tolerate cisplatin
This study is testing a new combination of immune treatments for bladder cancer patients who can't take cisplatin to see if it helps them before surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.